Can friends help stop HIV? new study tests sharing test kits and prevention info through social networks
NCT ID NCT06927856
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two strategies for getting HIV self-test kits and PrEP (a daily pill that prevents HIV) to people who might benefit. Current PrEP users will either directly give kits to friends or refer them to pick up kits. The goal is to see which method gets more people tested and connected to PrEP. About 320 people will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 320 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria - PrEP Clients (Egos): * Stated willingness to provide informed consent. * Stated willingness to comply with all study procedures. * Stated availability for the duration of the study. * Ability to identify members of their social network who may benefit from receiving an HIVST kit and PrEP information. * Currently prescribed PrEP by RAPID clinics, including those initiating PrEP on the same day as study enrollment. Inclusion Criteria for Peers (Alters): \- Provision of electronic informed consent prior to completion of the Quick Response (QR)-linked survey instruments. Exclusion Criteria for PrEP Clients (Egos): * Inability or refusal to provide informed consent (e.g., cognitive impairment). * Unable or unwilling to comply with study procedures per study investigator * Inability to identify members of their social network who may benefit from receiving an HIVST kit and PrEP information. * Aged 17 years or younger. Exclusion Criteria for Peers (Alters): * Failure to provide electronic informed consent prior to starting QR-linked Alter survey tools. * Age 17 years or younger.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Session couples program cut drug use and HIV risk?
- Decades of HIV data could reveal which treatments last
- Can testing together again keep male couples HIV-Free?
- Can a rapid HIV test get people treated sooner?
- Can Same-Day HIV prevention reach people before infection takes hold?
- New injectable HIV prevention drug tested in healthy volunteers